Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY) for possible violations of federal securities laws from June 17, 2015 through August 10, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired shares of Dr. Reddy’s during the Class Period, should contact the firm before the October 24, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, during the Class Period, Dr. Reddy's made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary, Betapharm Arzneimittel, located in Hyderabad, India, after a recent inspection of the plant. When this news reached the public, shares of Dr. Reddy's fell in value materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 477706

"/> DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Encourages Investors with Losses to Contact the Firm « MarketersMedia – Press Release Distribution Services – News Release Distribution Services
MarketersMEDIA Year End Sale is Finally Back! Get up to 70% OFF on your press releases. Hurry! Limited time only.
Click Here
How It Works? Plans & Pricing Our Distributions Newsroom Info Hub Sign Up Sign In Send Press Release Contact Sales
Contact Sales Sign Up Your Account Send Press Release
MarketersMEDIA / Newsroom / DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Encourages Investors with Losses to Contact the Firm

DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy’s Laboratories Limited and Encourages Investors with Losses to Contact the Firm

Share This Press Release

LOS ANGELES, CA / ACCESSWIRE / October 12, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY) for possible violations of federal securities laws from June 17, 2015 through August 10, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired shares of Dr. Reddy’s during the Class Period, should contact the firm before the October 24, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, during the Class Period, Dr. Reddy's made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary, Betapharm Arzneimittel, located in Hyderabad, India, after a recent inspection of the plant. When this news reached the public, shares of Dr. Reddy's fell in value materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 477706

LOS ANGELES, CA / ACCESSWIRE / October 12, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY) for possible violations of federal securities laws from June 17, 2015 through August 10, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired shares of Dr. Reddy’s during the Class Period, should contact the firm before the October 24, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here.

You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, during the Class Period, Dr. Reddy's made false and/or misleading statements, and/or failed to disclose, that the Company lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, Dr. Reddy's disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary, Betapharm Arzneimittel, located in Hyderabad, India, after a recent inspection of the plant. When this news reached the public, shares of Dr. Reddy's fell in value materially, which caused investors harm according to the Complaint.

Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 477706

Source URL: https://marketersmedia.com/deadline-approaching-lundin-law-pc-announces-securities-class-action-lawsuit-against-dr-reddys-laboratories-limited-and-encourages-investors-with-losses-to-contact-the-firm/249770

Source: AccessWire

Release ID: 249770

Our Client

Subscribe and Recieve exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2017 MarketersMedia – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).